Company Background
Foundation of the company and building of the production plant on the site at Santa Maria de Montcada (Barcelona), Spain.
Opening of the new factory in Celrà (Girona), Spain.
Plant in Celrà inspected and approved by the FDA
Approval was granted for the first product for the US market (specifically): Cyclobenzaprine HCl
ISO 9001 certification was obtained in Spain
- Extension of the production plant in Celrà, increasing our capacity in terms of reaction volume
- FDA inspection in Celrà resulted in no form 483 (no observations were noted)
- ISO 14001 certification was obtained in Spain
- Inauguration of a new Medichem laboratory with an extension of 200 m2 in Barcelona’s Science Park
- FDA inspection in Celrà resulted in no form 483 (no observations were noted) for the second consecutive time
- Opening of the extended Quality and R&D Laboratories in Celrà
- Investment to develop the Pilot Plant in Celrà
- Investment to develop the Physical Treatments Plant in Celrà
- Start of construction of new manufacturing facility in Malta
- Comprehensive environmental review of the manufacturing facilities
- Completion of new manufacturing plant in Malta
- Construction and completion of state-of-the-art water treatment facilities in Spain
- H.E. Dr. Edward Fenech-Adami, President of Malta, his wife and a delegation of the Maltese Government visited our facilities in Celrà, Spain.
- Start of regular production in Malta
- FDA Inspection of our plant in Celrà in Spain conducted in November resulted in no form 483 (no observations were noted) for the third consecutive time
- ISO 9001 certification was obtained in Malta
- Plant in Malta approved by the FDA in February.
- Extension of the R&D laboratory at the Barcelona Science Park.
- The latest FDA Inspection of our plant in Celrà in Spain conducted in April resulted in no form 483 (no observations were noted) for the fourth consecutive time
- ISO 14001 certification obtained in Malta